GSK2190915 Moderate to Severe Asthma Study
Condition: Asthma
MeSH terms: Asthma
Intervention: GSK2190195 100mg; Placebo
Intervention description: GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.; Placebo :
2% (w/w) Ethanol, sucralose (5 mg/100 mL of oral solution) to 100 % (w/w) aqueous sodium carbonate buffer (0.010 M, pH 9-10)
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment: 7.0
Sex: All
Minimum age: 18 Years
Maximum age: 65 Years
Healthy volunteers: No
Keywords: Sputum cell counts; Neutrophils; Severe Asthma; ICS; Inhaled corticosteroids

Summary:

      A randomised, double-blind, placebo-controlled, parallel group study to evaluate the effect
      of treatment with GSK2190915, a FLAP inhibitor, as add-on to current inhaled corticosteroid
      therapy in patients with moderate to severe asthma with elevated sputum neutrophils.
    

Eligibility criteria:

        Inclusion Criteria:

        A subject will be eligible for inclusion in this study only if all of the following
        criteria apply:

          -  Males and females aged 18 to 65 years inclusive.

          -  Body mass index within the range 18.5-37.0 kilograms/metre2 (kg/m2).

          -  An established clinical history of Asthma in accordance with the definition by the
             GINA Guidelines [GINA, 2006]. Subjects should have at screening or within the last
             year documented reversibility (>12 %) to short acting bronchodilator, or positive
             methacholine challenge, or positive histamine challenge (PC20 <8mg/ml).

          -  A female subject is eligible to participate if she is of: non-childbearing potential
             defined as pre-menopausal females with documented (medical report verification)
             hysterectomy or double oophrectomy or postmenopausal defined as 12 months of
             spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels >
             40 mIU/mL and estradiol < 40 pg/ml (<140 pmol/L) or 6 weeks postsurgical bilateral
             oophorectomy with or without hysterectomy; childbearing potential and agrees to use
             one of the contracception methods listed in Section 8.1 for an appropriate period of
             time prior to the start of dosing and until 3 months after last dose.

          -  Male subjects must agree to use one of the contraception methods listed in Section
             8.1. This criterion must be followed from the time of the first dose of study
             medication until 3 months after the last dose.

          -  Subject with moderate to severe asthma with forced expiratory volume in one second
             (FEV1) ≥ 50% of predicted.

          -  Subject who are on regular inhaled corticosteroids without or in combination with a
             regular long acting Beta 2 Agonist. The dose should be stable for at least 4 weeks
             before screening.

          -  Subjects who are taking a minimum of FP 250mg BID or equivalent.

          -  Persistent sputum neutrophilia defined by sputum neutrophils ≥ 65% with TTC < 15
             million cells/g with no evidence of eosinophilia (sputum eosinophils < 2%). Persistent
             is defined as the criteria being met at screening (or within the 6 months preceding
             screening) and on visit 1.

          -  Signed and dated written informed consent is obtained from the subject

          -  The subject is able to understand and comply with the protocol requirements,
             instructions and protocol-stated restrictions.

        Exclusion Criteria:

        A subject will not be eligible for inclusion in this study if any of the following criteria
        apply:

          -  Past or present disease, which as judged by the investigator or medical monitor, may
             affect the outcome of this study. These diseases include, but are not limited to,
             cardiovascular disease, malignancy, gastrointestinal disease, hepatic disease, renal
             disease, haematological disease, neurological disease, endocrine disease or pulmonary
             disease (excluding asthma but including but not confined to chronic bronchitis,
             emphysema, bronchiectasis, eosinophilic bronchitis or pulmonary fibrosis).

          -  Clinically significant abnormalities in safety laboratory analysis at screening.

          -  Subject has uncontrolled hypertension or is hypertensive at screening. Hypertension at
             screening is defined as persistent systolic BP >150 mmHg or diastolic BP > 90mmHg.

          -  History of asthma exacerbations or acute intercurrent respiratory illness (viral
             respiratory syndrome, bronchitis, pneumonia) for a four week period before the
             screening visit

          -  History of life-threatening asthma, defined as an asthma episode that required
             intubations and/or was associated with hypercapnoea, respiratory arrest and/or hypoxic
             seizures.

          -  Subject is unable to abstain from taking prescription or non-prescription drugs
             (including vitamins and dietary or herbal supplements) including non-steroidal
             anti-inflammatory drugs (NSAIDs), anti-depressant drugs, anti-histamines and
             anti-asthma, anti-rhinitis or hay fever medication, with the exception of ICS, LABA
             and short action beta agonists, from 14 days before screening until the follow-up
             visit unless in the opinion of the Investigator and sponsor the medication will not
             interfere with the study

          -  Administration of oral or injectable steroids within 6 weeks of screening.

          -  The subject has participated in a study with a new molecular entity during the
             previous 3 months or has participated in 4 or more clinical studies in the previous 12
             months prior to the first dosing day.

          -  Administration of anti -leukotrienne therapies for 14 days before screening and during
             the study.

          -  Administration of any vaccinations within 1 month of screening or during the study.

          -  Administration of biological therapies within 3 months of the screening visit or
             during the study

          -  Subject is undergoing allergen desensitisation therapy.

          -  Administration of OATP1B1 substrates from 2 weeks before dosing, and until all
             follow-up assessments are completed.

          -  There is a risk of non-compliance with study procedures.

          -  History of blood donation (500 mL) within 3 months of starting the clinical study.

          -  The subject regularly drinks more than 28 units of alcohol in a week if male, or 21
             units per week if female. One unit of alcohol is defined as a medium (125 ml) glass of
             wine, half a pint (250 ml) of beer or one measure (25 ml) of spirits.

          -  The subject has a screening QTc value of >450msec, PR interval outside the range 120
             to 220msec or an ECG that is not suitable for QT measurements (e.g. poorly defined
             termination of the T-wave).

          -  The subject has tested positive for hepatitis C antibody or hepatitis B surface
             antigen.

          -  The subject has tested positive for HIV antibodies.

          -  The subject has a positive pre-study urine drug or urine or breath alcohol screen. A
             minimum list of drugs that will be screened for include Amphetamines, Barbituates,
             Cocaine, Opiates, Cannabinoids and Benzodiazepines.